Oral TQB3473 Achieves a 56.8% Response Rate in Relapsed/Refractory ITP – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Bingjie Ding et al, adding:
”TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
This phase 1 trial found oral TQB3473 achieved a 56.8% response rate in relapsed/refractory ITP, with 600 mg daily showing the best efficacy-tolerability balance.”
Title: TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study
Authors: Bingjie Ding, Tiejun Gong, Xiangzhou Du, Xiaoming Li, Yinghui Lai, Zhenyu Yan, Rong Fu, Xin Du, Anqi Yang, Jiajia Zhu, Yiran Wang, Hu Zhou
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 2, 2026, 13:50Arnav Garcha: New Insights Into Platelet Transport in Arterial Flow
-
Oct 2, 2026, 13:49Alessandro Lucchesi: RiseMPN 2026 – Shaping the Future of MPN Treatment
-
Oct 2, 2026, 13:43Ronald Mahomane: Bangladesh Moves Toward Sustainable Hemophilia Treatment Access
-
Oct 2, 2026, 13:38Sathya-Prasad Burjonrappa: Pediatric Trauma and Deep Venous Thrombosis
-
Oct 2, 2026, 12:50Ravi C Dara: ADHAR 2026 – Red Cell Exchange in Sickle Cell Disease
-
Oct 2, 2026, 12:37David McIntosh: WeDonate Partners with Dr. Martens to Reward UK Blood Donors
-
Oct 2, 2026, 12:31Ahmed Salah El-Deen: HELLP Syndrome – An Obstetric Emergency
-
Oct 2, 2026, 12:28Swapnil Hiremath: Transitioning from Idiopathic Thrombocytopenia to Antiphospholipid Syndrome in Recurrent Severe Preeclampsia
-
Oct 2, 2026, 12:08Austin Camp: Learn How to Treat HIT from an ICU Pharmacist in 60 Seconds!